Crabb, Simon
Danson, Sarah J.
Catto, James W. F.
McDowell, Cathy
Lowder, James N.
Caddy, Joshua
Dunkley, Denise
Rajaram, Jessica
Ellis, Deborah
Hill, Stephanie
Hathorn, David
Whitehead, Amy
Kalevras, Mihalis
Huddart, Robert
Griffiths, Gareth
Funding for this research was provided by:
Cancer Research UK (C9317/A1990)
Article History
Received: 1 February 2018
Accepted: 8 March 2018
First Online: 3 April 2018
Ethics approval and consent to participate
: The trial received favourable ethical opinion from the North West-Haydock Research Ethics Committee (15/NW/0936) and has Health Research Authority (HRA) approval (IRAS 183621). All participants provide written informed consent to participate and are free to withdraw at any time.
: Not applicable.
: SC has received research funding from AstraZeneca, Clovis Oncology and Plexxikon and has undertaken advisory work or received speaker fees from Janssen, Roche and Astellas. JWFC has received funding from Roche for a medical lecture. JL is an employee of Astex Pharmaceuticals, who are supporting the trial through the Cancer Research UK Experimental Cancer Medicine Centres (ECMC) drug combination alliance (but where responsibility for the final protocol lies with SC, GG and the academic sponsor). All other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.